Last checked at 3 Mar 2020 07:00
3 March 2020
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Shareholding in Company and Director/PDMR Shareholding
The Company received notification yesterday from Vulpes Life Sciences Fund ("Vulpes") that on 28 February 2020 it purchased 256,424 Ordinary Shares of 1p in the capital of the Company ("Ordinary Shares") at 3.00p per Ordinary Share (the "Purchase"). Following the Purchase, Vulpes has a total direct and indirect interest in 65,203,158 Ordinary Shares, equivalent to approximately 22 per cent of the issued share capital of the Company.
The Company also announces that by virtue of Martin Diggle being a Director of the Company and a Director and Principal of Vulpes Investment Management, which manages Vulpes, he now has an interest in 65,203,158 Ordinary Shares, representing approximately 22 per cent of the issued share capital of the Company.
The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.
1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | Martin Diggle | ||||
Reason for the notification | ||||||
a) | Position/status: | Non-Executive Director | ||||
b) | Initial notification/Amendment: | Initial Notification | ||||
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a) | Name: | Proteome Sciences Plc | ||||
b) | LEI: | 213800Q62ICXANKU2986 | ||||
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 1p nominal value GB0003104196 | ||||
b) | Nature of the transaction: | Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s): |
| ||||
d) | Aggregated information: · Aggregated volume: · Price: | Single transaction as in 4 c) above
| ||||
e) | Date of the transaction: | 28 February 2020 | ||||
f) | Place of the transaction: | London Stock Exchange, AIM (XLON) | ||||
For further information:
Proteome Sciences plc |
| |
Dr Ian Pike, Interim Chief Executive Officer/ Chief Scientific Officer
| Tel: +44 (0)20 7043 2116 |
|
Richard Dennis, Chief Commercial Officer |
| |
| ||
Allenby Capital Limited (Nominated Adviser & Broker) |
| |
John Depasquale / Jeremy Porter
| Tel: +44 (0) 20 3328 5656 | |
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.